
Amgen Inc.
NASDAQ•AMGN
CEO: Mr. Robert A. Bradway
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 1983-06-17
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Contact Information
Market Cap
$183.17B
P/E (TTM)
26.1
23.6
Dividend Yield
2.8%
52W High
$346.38
52W Low
$253.30
52W Range
Rank18Top 3.4%
6.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$9.56B+12.40%
4-Quarter Trend
EPS
$5.98+13.47%
4-Quarter Trend
FCF
$4.25B+28.18%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Net Income Soars 84% Nine-month Net Income reached $6.378B, an 84% increase over prior year, driven by strong revenue performance.
Total Revenue Up 10% Total revenues for nine months hit $26.885B, marking a 10% increase, fueled by 11% growth in product sales.
Strong Diluted EPS Growth Diluted EPS was $11.77 for nine months, reflecting an 84% increase compared to $6.40 reported last year.
TEZSPIRE Sales Surge TEZSPIRE product sales grew 49% to $1.004B for nine months, driven by strong volume growth across regions.
Risk Factors
Medicare Price Setting Risk ENBREL faces negative profitability impact from CMS Medicare price setting beginning January 1, 2026, per IRA provisions.
Otezla Price Setting Ahead Otezla selected for Medicare price setting starting January 1, 2027, expecting further net selling price declines post-2027.
Biosimilar Competition Pressure Prolia and XGEVA patent expirations in US (Feb 2025) lead to expected sales erosion from biosimilar launches.
Ongoing IRS Tax Disputes Tax court decision on 2010-2015 IRS profit allocation dispute not expected until second half of 2026.
Outlook
Pipeline Investment Continues Expect continued spending growth on Later-Stage Clinical Programs, including investments related to the MariTide development.
Repatha Indication Expansion FDA broadened Repatha use in August 2025 for high-risk adults, removing prior cardiovascular disease diagnosis requirement.
Capital Allocation Strategy Plan to optimize capital structure via debt reduction, dividends ($2.38/share declared), and stock repurchases.
TEZSPIRE New Approval FDA approved TEZSPIRE in October 2025 for chronic rhinosinusitis with nasal polyps in patients 12+.
Peer Comparison
Revenue (TTM)
MRK$64.24B
PFE$62.79B
BMY$48.03B
Gross Margin (Latest Quarter)
MRK81.9%
GILD79.8%
PFE74.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MRK | $253.56B | 13.2 | 38.9% | 37.2% |
| ISRG | $203.13B | 73.8 | 16.1% | 0.0% |
| AMGN | $183.17B | 26.1 | 96.2% | 60.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.7%
Moderate Growth
4Q Net Income CAGR
72.5%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $9.56B+12.4%|EPS: $5.98+13.5%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $9.17B+9.3%|EPS: $2.66+91.4%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 2, 2025|Revenue: $8.15B+9.4%|EPS: $3.22-1633.3%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 14, 2025|Revenue: $33.42B+18.6%|EPS: $7.62-39.3%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $8.50B+23.2%|EPS: $5.27+63.2%MeetForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 7, 2024|Revenue: $8.39B+20.1%|EPS: $1.39-46.1%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 3, 2024|Revenue: $7.45B+22.0%|EPS: $-0.21-103.9%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 14, 2024|Revenue: $28.19B+7.1%|EPS: $12.56+3.1%Beat